Akthelia has closed an angel-led funding round. 12 new shareholders, many of whom are angel investors with pharma industry background, bought shares for a total of 31,5 mISK. In addition, Nýsköpunarsjóður atvinnulífsins extended and converted a bond amounting to 10,8 mISK to shares, bringing the total round to just over 42 mISK. 

We would like to thank the new shareholders for their trust and for joining us on our journey. Many of the new shareholders have a background in pharmaceutics and bring a valuable network along. The plan for the investment is to fund immediate value increasing activities for Akthelia, including preliminary tox and PK for AKT-013 and achieving proof of concept in an established animal model. However, in June 2019 RANNÍS selected Akthelia for a grant from their Vöxtur program. Total grant is 46 mISK over two years.